Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

8.250 -0.470 (-5.39%)
Streaming Delayed Price Updated: 12:57 PM EDT, May 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Organon & Co. Common Stock

< Previous 1 2 3 4 Next >
Organon & Co. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OGN
From DJS Law Group
Via Business Wire
OGN Investors Have Opportunity to Join Organon & Co. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Organon Reports Results for the First Quarter Ended March 31, 2025
From Organon & Co.
Via Business Wire
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors
From Organon & Co.
Via Business Wire
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025
From Organon & Co.
Via Business Wire
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
From Organon & Co.
Via Business Wire
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
From Organon & Co.
Via Business Wire
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older
From Organon & Co.
Via Business Wire
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
From Organon & Co.
Via Business Wire
Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025
From Organon & Co.
Via Business Wire
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Organon & Co.
Via Business Wire
FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
From Organon & Co.
Via Business Wire
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
From Organon & Co.
Via Business Wire
Organon Reports Results for the Third Quarter Ended September 30, 2024
From Organon & Co.
Via Business Wire
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
From Organon & Co.
Via Business Wire
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Organon & Co.
Via Business Wire
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. 
From Roivant Sciences
Via GlobeNewswire
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
From Organon & Co.
Via Business Wire
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
From Organon & Co.
Via Business Wire
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Organon & Co.
Via Business Wire
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Roivant Sciences
Via GlobeNewswire
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
From Organon & Co.
Via Business Wire
Organon Reports Results for the Second Quarter Ended June 30, 2024
From Organon & Co.
Via Business Wire
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
From Organon & Co.
Via Business Wire
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
From Organon & Co.
Via Business Wire
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Organon Announces Proposed $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Organon Reports Results for the First Quarter Ended March 31, 2024
From Organon & Co.
Via Business Wire
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
From Organon & Co.
Via Business Wire
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
From Organon & Co.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.